

# Anneke Geurts-Moespot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1168908/publications.pdf>

Version: 2024-02-01

36  
papers

1,237  
citations

394421

19  
h-index

377865

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1882  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. <i>Arthritis and Rheumatism</i> , 2005, 52, 3020-3029.	6.7	203
2	Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. <i>Cancer</i> , 2002, 95, 641-655.	4.1	104
3	Association between High Levels of Blood Macrophage Migration Inhibitory Factor, Inappropriate Adrenal Response, and Early Death in Patients with Severe Sepsis. <i>Clinical Infectious Diseases</i> , 2007, 44, 1321-1328.	5.8	98
4	Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy. <i>Seminars in Cancer Biology</i> , 2015, 31, 99-105.	9.6	69
5	Vascular Endothelial Growth Factor in Systemic Capillary Leak Syndrome. <i>American Journal of Medicine</i> , 2009, 122, e5-e7.	1.5	57
6	The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6194-6202.	7.0	51
7	Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans. <i>Hypertension</i> , 2013, 61, 1060-1065.	2.7	50
8	Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators. , 2000, 86, 760-767.		49
9	Therapeutic targeting of autophagy in cancer. Part I: Molecular pathways controlling autophagy. <i>Seminars in Cancer Biology</i> , 2015, 31, 89-98.	9.6	47
10	Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 1019-1025.	1.3	42
11	Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 128, 22-28.	1.1	42
12	Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. <i>Proteomics</i> , 2006, 6, 1427-1436.	2.2	39
13	Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. <i>Cancer</i> , 2004, 101, 486-494.	4.1	35
14	Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 6363-70.	7.0	32
15	MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. <i>Cytokine</i> , 2006, 36, 51-56.	3.2	31
16	Vascular endothelial growth factor in ovarian cyst fluid. <i>Cancer</i> , 2001, 91, 371-377.	4.1	29
17	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA. <i>Shock</i> , 2007, 27, 482-487.	2.1	29
18	Quality control of cathepsin-D measurement by the EORTC receptor study group. <i>European Journal of Cancer</i> , 1992, 28, 72-75.	2.8	27

#	ARTICLE	IF	CITATIONS
19	Possible role of the plasminogen activation system in human subfertility. <i>Fertility and Sterility</i> , 2007, 87, 619-626.	1.0	25
20	PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. <i>Radiotherapy and Oncology</i> , 2008, 86, 361-368.	0.6	20
21	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. <i>BJU International</i> , 2008, 102, 177-182.	2.5	19
22	Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. <i>BMC Cancer</i> , 2007, 7, 143.	2.6	17
23	Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. <i>Journal of the Society for Gynecologic Investigation</i> , 2003, 10, 105-109.	1.7	16
24	Effect of Reoxygenation on the Hypoxia-Induced Up-Regulation of Serine Protease Inhibitor PAI-1 in Head and Neck Cancer Cells. <i>Oncology</i> , 2006, 71, 282-291.	1.9	14
25	Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. <i>Clinical Immunology</i> , 2007, 123, 60-65.	3.2	13
26	The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer. <i>Thrombosis and Haemostasis</i> , 2004, 91, 514-521.	3.4	12
27	Development of an ELISA for Measurement of BCAR1 Protein in Human Breast Cancer Tissue. <i>Clinical Chemistry</i> , 2004, 50, 1356-1363.	3.2	12
28	Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. <i>Obstetrics and Gynecology</i> , 2001, 97, 404-408.	2.4	11
29	Application of a Newly Developed ELISA for BCAR1 Protein for Prediction of Clinical Benefit of Tamoxifen Therapy in Patients with Advanced Breast Cancer. <i>Clinical Chemistry</i> , 2004, 50, 1445-1447.	3.2	9
30	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. <i>Molecular Pharmaceutics</i> , 2014, 11, 4249-4257.	4.6	8
31	Prospective Biomarker Trials Chemo NO and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. <i>Breast Care</i> , 2008, 3, 3-3.	1.4	7
32	Scintillation Proximity Assay to Study the Interaction of Epidermal Growth Factor with its Receptor. <i>Journal of Receptors and Signal Transduction</i> , 1992, 12, 389-399.	1.2	6
33	Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1725-1735.	2.5	6
34	Complex congenital malformations and the impact of the plasminogen activator system and $\beta$ -hCG in amniotic fluid. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 135, 47-52.	1.1	5
35	Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 120-127.	2.2	3
36	Concerns about Mammaglobin Assays. <i>Clinical Chemistry</i> , 2005, 51, 474-475.	3.2	0